Evidence of safety and efficacy in Kaposi sarcoma, NHL, lung cancer, and liver cancer were found in a prospective phase 1 study of pembrolizumab in PLWH with a CD4 count > 100 cells/μL and advanced malignancy (19). This evidence concerns the gene CD4 and non-Hodgkin lymphoma.